Skip to main content

A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM AND AVIBACTAM

Clinical Trial Grant
Duke Scholars

Administered By

Pediatrics, Critical Care Medicine

Awarded By

Pfizer, Inc.

Start Date

December 9, 2024

End Date

December 31, 2026
 

Administered By

Pediatrics, Critical Care Medicine

Awarded By

Pfizer, Inc.

Start Date

December 9, 2024

End Date

December 31, 2026